Abstract
dc:description.abstractType 1 diabetes (T1D) is a chronic autoimmune disease caused by the destruction of pancreatic beta cells, resulting in lifelong dependence on exogenous insulin and ongoing risk of complications despite modern therapy. Stem-cell-based therapies have emerged as an alternative strategy for beta-cell replacement, offering some advantages when compared to whole organ pancreas and cadaveric islet therapies which are limited by donor scarcity and require immunosuppression to avoid rejection of the therapy. This study reviews the use of mesenchymal stem cells (MSCs), which act through immunomodulation and cytoprotective signaling that support residual islets, and human pluripotent stem-cell-derived islets (SC-islets) which provide a renewable source of insulin-secreting cells. Early studies of human embryonic stem cell (hESC)-derived pancreatic endoderm, autologous chemically induced pluripotent stem cell (CiPSC)-derived islets, and the allogeneic Zimislecel product demonstrate that SC-islets can restore endogenous insulin secretion, improve glycemic control, and in many cases achieve insulin independence under immunosuppression. However, these islets show partial immaturity, off-target endocrine populations, and are susceptible to immune attack. Encapsulation devices, gene-edited hypo immune islets, and localized immune modulation are being developed to reduce or eliminate systemic immunosuppression. Current data indicate that stem-cell-based strategies have progressed to clinically credible beta-cell replacement platforms that, with further improvements in cell quality, immune protection, and delivery, could become widely used disease-modifying therapies for T1D. However, it has been demonstrated that SC-beta graft cells can work, but not without avoiding the limitation of immunosuppression. By focusing on utilizing gene edited hypo immune cells, I believe we can manufacture SC-islets on a large scale while eliminating or reducing the need for chronic immunosuppression to make SC-islet therapy a sustainable and widespread T1D treatment.
Degree
thesis:*- Name thesis:degree_name
- Master of Science
- Level thesis:degree_level
- masters
- Discipline thesis:degree_discipline
- Medical Sciences
- Grantor
- Boston University
- Year dc:date.issued
- 2026
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Brady, Alyson
- Advisors dc:contributor.advisor
-
- Tornheim, Keith
- Bottenfield, Karen
- ORCID dc:identifier.orcid
Subjects
dc:subject × 1Rights
- Language dc:language.iso
- en_US
Identifiers
dc:identifier.*- Handle dc:identifier.uri
- https://hdl.handle.net/2144/52972